Cargando…

Quantification of HER family receptors in breast cancer

The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nuciforo, Paolo, Radosevic-Robin, Nina, Ng, Tony, Scaltriti, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389676/ https://www.ncbi.nlm.nih.gov/pubmed/25887735 http://dx.doi.org/10.1186/s13058-015-0561-8

Ejemplares similares

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy
por: Nuciforo, Paolo, et al.
Publicado: (2015)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”
por: To, Nhu Hanh, et al.
Publicado: (2022)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS
por: Raina, Deepak, et al.
Publicado: (2013)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization
por: Annaratone, Laura, et al.
Publicado: (2017)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
por: Dupouy, Diego G., et al.
Publicado: (2016)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Peckys, Diana B., et al.
Publicado: (2021)

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial
por: Barber, Paul R, et al.
Publicado: (2019)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
por: Serra, V, et al.
Publicado: (2011)

Overview of the relevance of PI3K pathway in HR-positive breast cancer
por: Vasan, N, et al.
Publicado: (2019)

Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer
por: Inoue, Kazushi, et al.
Publicado: (2015)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells
por: Ferrand, Nathalie, et al.
Publicado: (2022)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019)

Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy
por: Fatima, Iqra, et al.
Publicado: (2021)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
por: Andrahennadi, Samitha, et al.
Publicado: (2021)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
por: Mitri, Zahi, et al.
Publicado: (2012)

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update
por: Mohanty, Swati Sucharita, et al.
Publicado: (2020)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: Griguolo, G., et al.
Publicado: (2021)

The Role of her4 in Inner Ear Development and Its Relationship with Proneural Genes and Notch Signalling
por: Radosevic, Marija, et al.
Publicado: (2014)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
por: Pupa, Serenella M., et al.
Publicado: (2021)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3dl63ne7qvbihhf8l2dhk44834